Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1950 1
1951 1
1952 1
1955 1
1957 2
1958 2
1959 2
1964 1
1966 1
1969 1
1970 1
1971 1
1975 1
1976 1
1977 1
1978 3
1979 1
1980 1
1981 2
1982 11
1983 5
1984 8
1985 8
1986 9
1987 6
1988 7
1989 8
1990 8
1991 6
1992 6
1993 8
1994 3
1995 3
1996 6
1997 3
1998 7
1999 11
2000 11
2001 5
2002 7
2003 5
2004 5
2005 8
2006 12
2007 13
2008 18
2009 23
2010 21
2011 11
2012 14
2013 10
2014 15
2015 23
2016 15
2017 14
2018 14
2019 19
2020 22
2021 19
2022 17
2023 21
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

464 results

Results by year

Filters applied: . Clear all
Page 1
OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005.
Saghari M, Gal P, Gilbert S, Yateman M, Porter-Brown B, Brennan N, Quaratino S, Wilson R, Grievink HW, Klaassen ES, Bergmann KR, Burggraaf J, van Doorn MBA, Powell J, Moerland M, Rissmann R. Saghari M, et al. Among authors: gal p. Clin Pharmacol Ther. 2022 May;111(5):1121-1132. doi: 10.1002/cpt.2539. Epub 2022 Mar 1. Clin Pharmacol Ther. 2022. PMID: 35092305 Free PMC article. Clinical Trial.
Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy.
Haddad G, Lorenzen JM, Ma H, de Haan N, Seeger H, Zaghrini C, Brandt S, Kölling M, Wegmann U, Kiss B, Pál G, Gál P, Wüthrich RP, Wuhrer M, Beck LH, Salant DJ, Lambeau G, Kistler AD. Haddad G, et al. Among authors: gal p. J Clin Invest. 2021 Mar 1;131(5):e140453. doi: 10.1172/JCI140453. J Clin Invest. 2021. PMID: 33351779 Free PMC article.
Proprotein Convertases and the Complement System.
Dobó J, Kocsis A, Dani R, Gál P. Dobó J, et al. Among authors: gal p. Front Immunol. 2022 Jul 6;13:958121. doi: 10.3389/fimmu.2022.958121. eCollection 2022. Front Immunol. 2022. PMID: 35874789 Free PMC article. Review.
Evolution of Cancer Progression in the Context of Darwinism.
Lacina L, Čoma M, Dvořánková B, Kodet O, Melegová N, Gál P, Smetana K Jr. Lacina L, et al. Among authors: gal p. Anticancer Res. 2019 Jan;39(1):1-16. doi: 10.21873/anticanres.13074. Anticancer Res. 2019. PMID: 30591435 Review.
MASP-1 Increases Endothelial Permeability.
Debreczeni ML, Németh Z, Kajdácsi E, Schwaner E, Makó V, Masszi A, Doleschall Z, Rigó J, Walter FR, Deli MA, Pál G, Dobó J, Gál P, Cervenak L. Debreczeni ML, et al. Among authors: gal p. Front Immunol. 2019 May 3;10:991. doi: 10.3389/fimmu.2019.00991. eCollection 2019. Front Immunol. 2019. PMID: 31130964 Free PMC article.
Soy and breast cancer: focus on angiogenesis.
Varinska L, Gal P, Mojzisova G, Mirossay L, Mojzis J. Varinska L, et al. Among authors: gal p. Int J Mol Sci. 2015 May 22;16(5):11728-49. doi: 10.3390/ijms160511728. Int J Mol Sci. 2015. PMID: 26006245 Free PMC article. Review.
464 results